LOS ANGELES (Reuters) -Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

With the launch of Wegovy by Danish pharmaceutical giant Novo Nordisk and US major Eli Lilly’s Mounjaro already in ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Danish pharma giant Novo Nordisk on Tuesday launched its blockbuster weight loss drug Wegovy as a once-a-week injection in ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

Diabetes drug Ozempic and weight-loss jab Wegovy may also reduce the risk of dementia, according to a new study. American ...

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

As Wegovy ushers in a new wave of weight-loss drugs to tackle India's growing obesity crisis, Dr. Rishma Pai sheds light on their use in obese women dealing with PCOS, infertility, and menopausal ...

Novo Nordisk has introduced Wegovy, a once-weekly weight loss injection, in India. The drug aims to manage obesity and reduce ...